TWO of the seven experts advising the government on national guidelines for Attention Deficit Hyperactivity Disorder have links to ADHD drug companies, new conflict-of-interest declarations show. Westmead adolescent health expert Michael Kohn, who has been appointed to the National Health and Medical Research Council working group, was paid by Eli Lilly, the maker of the ADHD drug Strattera, to develop educational material.
AUSTRALIA’S ADHD guidelines are being redeveloped as a US psychiatrist whose work is heavily cited in existing draft guidelines has been sanctioned by Harvard University for violating conflict-of-interest rules.
Professor Joseph Biederman and two colleagues, Thomas Spencer and Timothy Wilens, were investigated by Harvard after allegedly failing to report to the university millions of dollars they received from drug firms.
In 2006, The New York Review of Books reported that four-year-old Rebecca Riley died of the effects of two prescription drugs—Clonidine and Depakote.
These medications, along with Seroquel, were prescribed for Rebecca after she was diagnosed, at the age of two, with attention deficit hyperactivity disorder (ADHD) and bipolar disorder. The three drugs are not approved by the Food and Drug Administration (FDA) for treatment of ADHD or long-term treatment of bipolar disorder, nor are they approved for children as young as Rebecca.
The New York Review of Books‘ recent two-part article (1) by Marcia Angell on the treatment of mental illness with psychoactive drugs (those that affect the mental state) addresses an issue that may one day prove very important to investors in pharmaceutical stocks. (All statistics and quotations herein are drawn from Dr. Angell’s article.) It is not illegal for a doctor to prescribe a drug off-label, that is, for a non-FDA-approved use, but a drug marketer cannot lawfully encourage a doctor to do so. The profits in psychoactive drugs, however, make it tempting to flout the law. In the past four years, AstraZeneca (AZN), Pfizer (PFE), Eli Lilly (LLY), Bristol-Myers Squibb (BMY) and Forest Labs (FRX) have all settled federal charges of marketing psychoactive drugs off-label, at a cost running into hundreds of millions.
Ritalin and other psychotropic medication for children are a “quick fix” and the government should urgently review their use, psychologists have urged.
The Association of Educational Psychologists (AEP) fears there is insufficient data on the effects such drugs have on child development.
Captured in a family video, Harry Hucknall gives a cheeky grin before whizzing off down the street on his new bike. His father, Darren, will never forget the moment — when Harry was seven — and often watches the scene again and again.
It is a precious memory of Harry who, one Sunday evening in September last year, kissed his mother Jane and older brother, David, goodnight before going upstairs to his bedroom and locking the door. He then hanged himself with a belt from his bunk bed.
He was ten years old.
His father blames Harry’s death on two ‘mind-altering’ drugs that his son had been prescribed by a psychiatrist to cure his boisterous behaviour and low spirits.